Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating restated by stock analysts at Cantor Fitzgerald in a report issued on Monday, March 12th. They currently have a $50.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 203.77% from the stock’s current price.
The analysts wrote, “Takeways from the quarter that support our positive thesis: 1) Approval of Eskata for SK in mid-December, 2) A productive R&D Day on 10/4/17, 3) The initiation of three Phase 2 trials of ATI-502 to treat Alopecia Areata (AA) and the initiation of a Phase 2 trial of ATI-502 to treat vitiligo, 4) The presentation of pre-clinical data on ATI-450 at the American College of Rheumatology annual meeting, suggesting the potential for ATI-450 as an oral treatment for Cryopyrin associated periodic syndromes (CAPS) in November, And 5) Cash and equivalents totaled $208.9MM at 12/31/17, which should fund operations through 2H19.””
Several other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Guggenheim initiated coverage on shares of Aclaris Therapeutics in a report on Thursday, February 8th. They issued a “buy” rating and a $53.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $43.50.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.80 million. equities analysts anticipate that Aclaris Therapeutics will post -4.27 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. MetLife Investment Advisors LLC purchased a new stake in Aclaris Therapeutics during the fourth quarter valued at $244,000. Redmile Group LLC increased its position in Aclaris Therapeutics by 6.0% during the fourth quarter. Redmile Group LLC now owns 107,020 shares of the biotechnology company’s stock valued at $2,639,000 after acquiring an additional 6,060 shares during the last quarter. Millennium Management LLC bought a new position in Aclaris Therapeutics during the fourth quarter valued at $291,000. Teachers Advisors LLC increased its position in Aclaris Therapeutics by 8.4% during the fourth quarter. Teachers Advisors LLC now owns 42,099 shares of the biotechnology company’s stock valued at $1,038,000 after acquiring an additional 3,273 shares during the last quarter. Finally, Deutsche Bank AG increased its position in Aclaris Therapeutics by 29.4% during the fourth quarter. Deutsche Bank AG now owns 179,622 shares of the biotechnology company’s stock valued at $4,426,000 after acquiring an additional 40,784 shares during the last quarter. Institutional investors and hedge funds own 92.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/2018/04/07/cantor-fitzgerald-reiterates-buy-rating-for-aclaris-therapeutics-acrs/2038357.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.